PriMera Scientific Medicine and Public Health (ISSN: 2833-5627)

Review Article

Volume 2 Issue 6

Review on CoviShield and Covaxin Vaccine against Covid-19

Prashant B Patil, Dipak M Patil, Zamir G Khan, Sai A Patel, Jayvadan K Patel*

May 29, 2023

View PDF

Abstract

Since the pandemic began, India has confirmed more than 35 million cases and 50 lakh deaths (COVID19). The country has the second-highest number of Covid-19 infections in the world. As a result, vaccines that are both safe and effective required. The most widely used vaccinations in India are CoviShield and Covaxin. While the Serum Institute of India in Pune produces CoviShield, Covaxin is wholly designed, developed, and manufactured in India. CoviShield, a viral vector vaccine developed, it delivers spike proteins and mounts a tolerable immune response to a live virus using an adenovirus discovered in chimps, ChAD0x1. Covaxin is an inactivated coronavirus vaccine. India has reached the milestone of more than 1 billion vaccination doses. In addition, India achieves a world record by administering 2.5 million vaccines in a single day. The major goal of this research is to distinguish between the two most often used vaccinations in India, CoviShield and Covaxin. Also everyone in the public is aware of how it works, safe, effective and harmful it is. As a result of these vaccines, India plays a critical role in halting the coronavirus in the present and near future, perhaps saving millions of lives.

Keywords: CoviShield; Covaxin; Vaccine; Covid-19; India; Virus

References

  1. Bukhari MH, M Syed and S Zain. “The Differences between Traditional Vaccines and RNA Vaccines: Safety, Efficacy, Reliability and Future of COVID-19 Vaccines”. Annals of King Edward Medical University 27.2 (2021).
  2. Zheng H and JJ Cao. “ACE gene polymorphism and severe lung injury in patients with COVID-19”. The American journal of pathology (2020).
  3. Dai L and GF Gao. “Viral targets for vaccines against COVID-19”. Nature Reviews Immunology 21.2 (2021): 73-82.
  4. Lipworth B, C Kuo and R Chan. “Emerging pharmacotherapy for COVID-19”. Journal of the Royal College of Physicians of Edinburgh 50.2 (2020): 133-137.
  5. Cheng H, Y Wang and GQ Wang. “Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19”. Journal of medical virology 92.7 (2020): 726-730.
  6. Pillaiyar T, S Meenakshisundaram, and M Manickam. “Recent discovery and development of inhibitors targeting coronaviruses”. Drug discovery today 25.4 (2020): 668-688.
  7. Dhama K., et al. “COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics”. Human vaccines & immunotherapeutics 16.6 (2020): 1232-1238.
  8. Deb B, H Shah and S Goel. “Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials”. Journal of biosciences 45.1 (2020): 1-10.
  9. Le TT., et al. “Evolution of the COVID-19 vaccine development landscape”. Nat Rev Drug Discov 19.10 (2020): 667-668.
  10. Basavaraja CK., et al. “Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India”. Therapeutic Advances in Vaccines and Immunotherapy 9 (2021): 25151355211055833.
  11. Shahzamani K., et al. “Vaccine design and delivery approaches for COVID-19”. International Immunopharmacology 100 (2021): 108086.
  12. Uttarilli A., et al. “Super-rapid race for saving lives by developing COVID-19 vaccines”. Journal of Integrative Bioinformatics 18.1 (2021): 27-43.
  13. Callway E. “Oxford covid vaccine results puzzle scientists”. Nature 588 (2020): 16-18.
  14. Mascellino MT., et al. “Overview of the Main Anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety”. Infection and drug resistance 14 (2021): 3459.
  15. Garofalo M., et al. “Prospects of replication-deficient adenovirus based vaccine development against SARS-CoV-2”. Vaccines 8.2 (2020): 293.
  16. Kurup D and MJ Schnell. “SARS-CoV-2 vaccines–The biggest medical research project of the 21st century”. Current Opinion in Virology (2021).
  17. Angeli F., et al. “SARS-CoV-2 vaccines: Lights and shadows”. European Journal of Internal Medicine (2021).
  18. Miller JM., et al. “Guidelines for safe work practices in human and animal medical diagnostic laboratories”. MMWR Surveill Summ 6.61 (2012): 1-102.
  19. Nikhra V. Evolving COVID-19 Pandemic: The Lurking Dangers and Pillars of Hope.
  20. Zahid A. Johnson & Johnson Vaccine Update.
  21. Huang KY., et al. “Humanized COVID‐19 decoy antibody effectively blocks viral entry and prevents SARS‐CoV‐2 infection”. EMBO molecular medicine 13.1 (2021): e12828.
  22. Shrestha Y., et al. “Covid-19 Vaccine Authorized in India-A Mini Review”. (2021).
  23. Voysey M., et al. “Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK”. The Lancet 397.10269 (2021):  99-111.
  24. Analytica O. “India’s vaccine roll-out faces key obstacles”. Expert Briefings (2021).
  25. Darbar S, S Agarwal and S Saha. “COVID19 Vaccine: COVAXIN®-India’s First Indigenous Effective Weapon to Fight against Coronavirus (A Review)”. Parana Journal of Science and Education 7.3 (2021): 1-9.
  26. Srivastava R, P Ish and S COVID. “The initial experience of COVID-19 vaccination from a tertiary care centre of India”. Monaldi Archives for Chest Disease (2021).
  27. Majumdar S., et al. “Perspectives about modulating host immune system in targeting SARS-CoV-2 in India”. Frontiers in genetics 12 (2021): 125.
  28. Wani R, PH Manihar and VJ Wani. “Covid-19 Vaccination: Part Played in Pregnancy”. The Indian Practitioner 74.3 (2021): 7-10.
  29. Sharma P and G Pardeshi. “COVID-19 vaccination in India: An ethical perspective”. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15.6 (2021): 102314.
  30. Abdulla ZA., et al. “A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development”. Pathogens 10.7 (2021): 788.
  31. Kumar M., et al. “A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics”. Plants 10.6 (2021): 1213.
  32. Gharate JS, SA Daitkar and KA Aher. Approved Covid 19 Vaccines: A Review (2021).
  33. Abduljaleel Z, FA Al-Allaf and SA Aziz. “Peptides-based vaccine against SARS-n CoV-2 antigenic fragmented synthetic epitopes recognized by T cell and β-cell initiation of specific antibodies to fight the infection”. Bio-design and Manufacturing (2021): 490-505.
  34. Sapkal GN., et al. “Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B. 1.1. 7 variant of SARS-CoV-2”. Journal of Travel Medicine 28.4 (2021): taab051.
  35. Singh AK., et al. “Antibody Response after First-dose of ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study”. medRxiv (2021).
  36. Sharma R, S Tiwari and A Dixit. “Covaxin: An overview of its immunogenicity and safety trials in India”. Bioinformation (2021): 840-840.
  37. Nikhra V. “Stages in COVID-19 vaccine development: The Nemesis, the Hubris, and the Elpis”. Int J Clin Virol 4 (2020): 126-135.
  38. Cohen J. “Doses of reality”. American Association for the Advancement of Science (2021).
  39. Sharma M. “Story of the biggest vaccination drive in the world so far”. Journal of pharmacovigilance and drug research 2.2 (2021): 1-2.
  40. Zare H., et al. “Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran”. International immunopharmacology 101 (2021): 108351.
  41. Ella R., et al. “Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial”. MedRxiv (2021).
  42. Dar MA., et al. “Safety, efficacy, and immunogenicity of COVAXIN: A review”. Journal of Applied Pharmaceutical Science 11.11 (2021): 018-025.
  43. Rotbi MF, S Motahhir and AE Ghzizal. “Blockchain technology for a Safe and Transparent Covid-19 Vaccination”. arXiv preprint arXiv:2104.05428 (2021).
  44. Bobdey S, S Kaushik and A Menon. “The conundrum of two-dose interval of ChAdOx1 nCOV-19 corona virus vaccine: Way ahead”. Medical Journal, Armed Forces India 77 (2021): S250.